No two tumors are alike, and every treatment ought to be just as specific.

How you can use Molecular Health Guide® to identify the appropriate drug-based treatment options for your patients – from the very beginning.

Precision medicine in oncology

We know that doctors always try to base their decisions about the best-possible treatment for a given patient based not only on the diagnosis itself. They also incorporate information about the patient’s characteristics, such as age, physical constitution, the desire to have a child, and, if appropriate, family medical history.
What is new is that modern diagnostics allow physicians to document the genetic, molecular and cellular characteristics of each patient and use this information to make decisions about whether a given treatment is an option. This is how personalized medicine complements oncological treatment as it has been practiced to date.

The era of precision medicine is dawning

How you can make customized therapeutic decisions based on molecular genetics

Working with DNA sequences, Molecular Health transforms genetic patient data into clinically viable information so that the most efficacious and safest drug-based option can be determined for every oncology patient.

Precision medicine becoming reality

The bioinformatic analysis of mutations occurs by means of MH Guide, a registered medical device. This special software is linked to a comprehensive proprietary database to find the most potentially efficacious and safest cancer treatment for the patient’s respective tumor profile or to suggest a clinical trial for your patient who has exhausted other treatment options. Furthermore, you can also orient your approach along clinical guidelines to prevent unnecessary treatments (resistance biomarkers) and learn more about potential severe or common adverse events. Drug interactions are cited as well. The findings of the analysis will support you in your therapeutic decision.

Using MH Guide

After sequencing the tissue specimens, the data derived from the analysis are integrated and assessed at Molecular Health along with the patient’s clinical data to generate a molecular genetic tumor profile. The MH Guide-certified physician then generates a report and presents it to the treating physician as a qualified and nuanced therapeutic recommendation (for details, see below)). If you wish to undergo training and certification to use MH Guide yourself, please feel free to contact.

MH Guide functions:

MATCHING


  • Patient-specific information from the genetic material of the tumor is compared with the latest knowledge published in biomedical journals
  • References are provided to recruiting clinical studies which correspond to the patient’s indication

PROFILING


  • A comprehensive molecular-genetic tumor profile is created as the basis for subsequent analysis and customized therapeutic options
  • The drug safety risk factors (resistance and toxicity biomarkers) are analyzed
  • A report is generated based exclusively on evidence-based information derived from Dataome® and quality-assured processes

REPORTING


  • There is complete transparency about the approval and development status of study drugs as well as information about approved drugs and biomarkers
  • The report can be enhanced and complemented by your own expertise

Tumor profiling

MH Guide analyses rely on data about the tumor which are derived from sequencing the genetic material. Depending on the tumor and staging, there are two potential procedures:

MH Guide panel


focuses on a set of over 600 genes defined by Molecular Health. This panel was selected based on its medical significance and therapeutic relevance in oncology. The analysis facilitates hypotheses about intelligent drug-based therapeutic options and risk factors when selecting particular active substances, and this serves as the basis for a customized treatment plan.

MH Guide whole exome


expands the analysis to include the complete set of over 20,000 functional genes – all of the regions which contain protein-coding genes. In addition to the information that can be derived from the MH Guide panel, this analysis provides information about complex contexts between individual genetic mutations, drug efficacy and mechanisms of disease.

How you as an oncologist can benefit from MH Guide

Having a reliable decision-making platform from the very beginning that assists you as the treating physician in analyzing molecular patient data to select the appropriate drug-based therapy

Preventing severe or more common adverse effects and unnecessary treatments

Supporting you in optimizing therapeutic decisions for your oncology patients who are in advanced stages of disease or for those who have exhausted the possibilities of standard treatments

Informing you about relevant clinical trials for your patients

MH Guide: The step-by-step procedure for you as the treating physician

.

The consultation between the physician and patient
As the treating physician, you first meet with your patient to discuss the option of a DNA analysis of the tumor using MH Guide.

Contacting a MH Guide-certified physician
You then contact an MH Guide-certified colleague to discuss the next steps in preparing the analysis. Our Customer Care Team can assist you in initiating this contact.

Preparing the analysis
You receive all of the relevant information and forms needed to prepare the analysis.

.

Order
The MH Guide-certified physician sends the order for sequencing the tumor DNA and the subsequent MH Guide analysis. The following tasks are coordinated with your assistance:

  • Conducting patient-information discussions and receiving written consent for genetic analysis as mandate by the German Genetic Diagnostic Act.
  • Organizing the sample-preparation process as described in the sample-collection process.
  • Coordinating the logistics.

Sequencing
In a certified laboratory, the DNA of the samples is decoded by means of next-generation sequencing. The sequencing data are transferred to Molecular Health via secure data access.

Findings
The sequencing data are analyzed along with the clinical patient data at Molecular Health to define the tumor’s characteristics. The MH Guide-certified physician then generates a report and presents it to the treating physician as a qualified treatment recommendation.

.

The consultation between the physician and patient
You discuss the findings and therapeutic options with your patient as well as talking about potentially taking part in suitable clinical trials.

Who pays for the costs of a MH Guide analysis?

For the most part, having an MH Guide analysis conducted is (still) considered an out-of-pocket expense, and in most cases you will have to cover the costs yourself. Please contact us for more information: CustomerCareEU@molecularhealth.com

MH Guide-certified physicians and laboratories in Germany

You can request a list of all of the MH Guide-certified physicians and laboratories in Germany here.

Mr.Mrs.
I agree that my name, email address, and any other information I provide, can be transferred to Molecular Health GmbH and processed there for the purpose of answering my request. I have read the privacy policy and hereby agree that my personal data may be processed as described. I can revoke this agreement at any time.

[recaptcha]

Certification program for physicians in oncology

Are you a physician who is interested in becoming MH Guide-certified physician? – Then you can request information about our certification program for physicians in oncology .

To use a medical device such as MH Guide, you have to take part in certification training to learn how to use and apply the software. As an MH Guide user, you can always turn to our Customer Care Team about organization matters, and if there are technical questions, you can consult with our Scientific Field Support Team of scientists with doctoral degrees. We also welcome your suggestions about new product features and content that will help us continue to optimize MH Guide.

Someone from our Customer-Care-Team would be glad to assist you.

Certified quality and data privacy

MH Guide is registered in Europe as an in vitro diagnostic medical device (IVD), which means it is subject to strict monitoring and regulation. MH Guide works only with pseudonymized data; we learn only the indication, sex, age and ethnicity of the patient. No other personal identifying information is communicated or saved. Only you as the treating physician and the MH Guide-certified physician have access to any other personal identifying information. See also Quality and Safety